First-in-class multimodal intracardiac catheter unifying three sensing technologies with AI-powered real-time tissue classification.
Cardiovascular disease remains the leading cause of mortality worldwide. Conditions like cardiac amyloidosis and myocardial fibrosis progress silently — often undetected until irreversible damage has occurred.
No existing intracardiac tool simultaneously characterizes the biochemical, electrical, and mechanical state of heart muscle in real time at the point of contact during a live procedure.
An 8 Fr deflectable catheter integrating hyperspectral optics, bio-impedance mapping, and piezoelectric micro-elastography — fused by CardioSpectra-AI™ for real-time 3D tissue classification.
450 – 1000 nm · VIS–NIR
Chromophore content, autofluorescence & scattering coefficients. Detects amyloid deposits, collagen density, and ischemia markers at molecular level.
Pt-Ir Electrodes · 4-Ring Array
Tissue conductivity & cellular integrity profiling. Maps electrical substrate, distinguishes scar from border zone with contact-quality feedback.
0.5 – 5 MHz · PZT + PVDF
Myocardial stiffness (kPa), shear wave velocity & viscoelasticity. Quantifies fibrosis (25–60 kPa) and amyloid infiltration (60–100+ kPa).
8 Fr deflectable catheter with real-time 3D tissue classification. Compatible with existing EP infrastructure — no new capital equipment required.
Miniaturized sensing in pacemaker leads. Continuous myocardial monitoring with <1% duty cycle.
Real-time Electro-Structural Digital Twin with graph-neural-network tissue classification and confidence-weighted mapping.
Population-level analytics platform. Multi-center learning for model improvement and drift detection.
System architecture, phantom testing, provisional patent filed, SBIR Phase I proposal.
Optical subsystem, sensor integration, bench-test cardiac phantoms, early AI classifier.
Porcine/bovine studies, histology correlation, AI fusion model V2, ISO 13485 prep.
First-in-Human (n≈20), FDA Pre-Submission, QMS implementation, Series A.
Multicenter trial (n≈100–150), 510(k)/De Novo, FusionSuite beta at 5 sites.
FDA clearance, CE Mark EU, Lite OEM launch, global SaaS rollout.
Inventor · Principal Investigator
Physician-innovator and cardiovascular medicine specialist at Brookdale University Hospital Medical Center, Brooklyn, NY. Combines deep clinical insight in cardiology with a rigorous engineering approach to medical device innovation.
Co-Investigator · Brookdale University Hospital
Co-Investigator · Brookdale University Hospital
Target: JACC Clinical Electrophysiology
Presented to panelists · 2025
Demonstrating clinical and scientific merit
Cardiovascular interventional conference
Platform grounded in 15+ peer-reviewed studies including TOCCASTAR, DECAAF, Fire-and-Ice, SMART-SF, and foundational cardiac spectroscopy research.
We welcome inquiries from clinical collaborators, research partners, and industry leaders interested in advancing intracardiac diagnostics.